Mainz Biomed secured $6 million in a private placement and plans to divest ColoAlert as it pivots from colorectal cancer screening to build a pancreatic cancer detection program for the U.S. market.
Longevity News
Mainz Biomed, maker of the ColoAlert test, inked a private placement deal for $6 million and is looking to shed its c...
Source: FierceBiotech - All • Published: 20 Feb 2026, 23:17
Continue exploring
Related longevity signals
Longevity TechnologyClaremedica’s digital test finds 90% of new dementia cases earlyA report on a primary care group’s adoption of a digital cognitive assessment and what readers will learn about its implementation and uptake.Lifespan.ioA Million-Person Study Finds a Protective Metabolic GeneHuman genetics research exploring metabolic regulation and disease risk, previewing an article that examines gene-based discoveries and potential therapeutic pathways.PR NewswireAureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug DiscoveryA biotech funding story about a startup scaling AI-native drug discovery and building biological foundation models; a look at its R&D strategy and platform.Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.